PaySign Inc. (PAYS)

Paysign posted strong Q2 2025 results, with 33% YoY revenue growth and robust Pharma segment momentum, driven by US tariffs and new client wins. PAYS is rated a hold, as the stock trades at fair value...

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. Appoints Jose Garcia as Executive Vice President, Life Science Solutions.

HENDERSON, Nev.--(BUSINESS WIRE)--Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions.

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. Announces Election of Dan Henry as Chairman of the Board.

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. to Present at the Oppenheimer Technology, Internet & Communications Conference.

Paysign, Inc. (NASDAQ:PAYS ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants Jeffery B. Baker - CFO & Treasurer Mark R.

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. Reports Second Quarter 2025 Financial Results.

Investors who want to keep buying stocks in July and throughout the second half of 2025 might consider adding exposure to highly-ranked cheap stocks that trade for $10 a share or less.

Paysign (PAYS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Paysign has achieved strong double-digit revenue growth year-over-year and expanded its market share significantly. The company now controls about 50% of the plasma donation center market after adding...